Terms: = Prostate cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
12 results:
1. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced prostate cancer.
Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
[TBL] [Abstract] [Full Text] [Related]
2. Multifocal Extraprostatic Extension of prostate cancer.
Farchoukh L; Laframboise WA; Nelson JB; Bastacky S; Parwani AV; Dhir R
Am J Clin Pathol; 2020 Mar; 153(4):548-553. PubMed ID: 31825470
[TBL] [Abstract] [Full Text] [Related]
3. AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate prostate cancer Cell Stemness.
Wang X; Jin J; Wan F; Zhao L; Chu H; Chen C; Liao G; Liu J; Yu Y; Teng H; Fang L; Jiang C; Pan W; Xie X; Li J; Lu X; Jiang X; Ge X; Ye D; Wang P
Dev Cell; 2019 Feb; 48(3):345-360.e7. PubMed ID: 30595535
[TBL] [Abstract] [Full Text] [Related]
4. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.
Nicolatou-Galitis O; Kouri M; Papadopoulou E; Vardas E; Galiti D; Epstein JB; Elad S; Campisi G; Tsoukalas N; Bektas-Kayhan K; Tan W; Body JJ; Migliorati C; Lalla RV;
Support Care Cancer; 2019 Feb; 27(2):383-394. PubMed ID: 30353228
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of Vitronectin Expression in prostate cancer and the Clinical Significance of the Association of Vitronectin Expression with prostate Specific Antigen in Detecting prostate cancer.
Niu Y; Zhang L; Bi X; Yuan S; Chen P
Urol J; 2016 Mar; 13(1):2527-32. PubMed ID: 26945657
[TBL] [Abstract] [Full Text] [Related]
6. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
Fornaro L; Faviana P; De Gregorio V; Vivaldi C; Paolicchi E; Masi G; Loupakis F; Sensi E; Lupi C; Fontanini G; Wang Y; Danesi R; Falcone A; Crea F
BMC Cancer; 2015 Nov; 15():874. PubMed ID: 26553291
[TBL] [Abstract] [Full Text] [Related]
7. Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.
Chen M; Nowak DG; Trotman LC
Clin Cancer Res; 2014 Jun; 20(12):3057-63. PubMed ID: 24928944
[TBL] [Abstract] [Full Text] [Related]
8. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.
Hagberg Thulin M; Jennbacken K; Damber JE; Welén K
Clin Exp Metastasis; 2014 Mar; 31(3):269-83. PubMed ID: 24292404
[TBL] [Abstract] [Full Text] [Related]
9. cancer immunology--analysis of host and tumor factors for personalized medicine.
Ogino S; Galon J; Fuchs CS; Dranoff G
Nat Rev Clin Oncol; 2011 Aug; 8(12):711-9. PubMed ID: 21826083
[TBL] [Abstract] [Full Text] [Related]
10. prostate cancer risk variants are not associated with disease progression.
Szulkin R; Holmberg E; Stattin P; Xu J; Zheng S; Palmgren J; Grönberg H; Wiklund F
Prostate; 2012 Jan; 72(1):30-9. PubMed ID: 21520160
[TBL] [Abstract] [Full Text] [Related]
11. Clinical features and prognosis of patients with renal cancer and a second malignancy.
Antonelli A; Calza S; Arrighi N; Zani D; Corti S; Cozzoli A; Zanotelli T; Cunico SC; Simeone C
Urol Oncol; 2012; 30(3):294-300. PubMed ID: 20843710
[TBL] [Abstract] [Full Text] [Related]
12. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract] [Full Text] [Related]
